Maternal synapsin autoantibodies are associated with neurodevelopmental delay

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Maternal autoantibodies crossing the placenta can impact fetal neurodevelopment.
• Synapsin 1 (SYN1) is crucial for synaptic function; loss-of-function variants cause X-linked intellectual disability.
• The role of maternal anti-SYN1 autoantibodies in neurodevelopmental disorders is not well understood.

Purpose of the Study:

• To investigate the association between maternal anti-SYN1 autoantibodies and neurologic abnormalities in children.
• To determine if maternal SYN1 autoantibody seropositivity correlates with specific neurodevelopmental phenotypes.

Main Methods:

• Analysis of a clinical cohort of 208 mother-child pairs with neurologic abnormalities.
• Serological testing for maternal autoantibodies against Synapsin 1 (SYN1).
• Correlation of maternal seropositivity with child's neurologic and developmental outcomes.

Main Results:

• Maternal anti-SYN1 autoantibody seropositivity was identified in 9.6% of mothers.
• Seropositivity was associated with a higher risk of intellectual disability and behavioral problems in children.
• Children of seropositive mothers showed increased incidence of epilepsy, macrocephaly, and developmental delay, mirroring SYN1 loss-of-function phenotypes.

Conclusions:

• Maternal autoantibodies targeting Synapsin 1 (SYN1) are associated with adverse neurodevelopmental outcomes in offspring.
• The findings suggest a potential pathogenic role or biomarker utility of anti-SYN1 autoantibodies in conditions like intellectual disability and epilepsy.
• Further functional studies are needed to elucidate the direct pathogenic mechanisms of anti-SYN1 autoantibodies in neurodevelopment.